Complete if Known Substitute for form 1449A/PTO Application Number 10/660,202 INFORMATION DISCLOSURE Filing Date September 11, 2003 STATEMENT BY APPLICANT First Named Inventor Örn Almarsson (use as many sheets as necessary) Art Unit 1617 Examiner Name Deirdre R. Claytor Sheet of Attorney Docket Number 6

TPI.350C1

			U.S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-2,665,277	01-05-1954	Homeyer et al.	All
	U2	US-3,970,651	07-20-1976	Kaplan et al.	All
	U3	US-4,925,674	05-15-1990	Giannini et al.	All
	U4	US-4,927,855	05-22-1990	Lafon	All
	U5	US-4,994,604	02-19-1991	Tung et al.	All
	U6	US-5,023,092	06-11-1991	DuRoss	All
	U7	US-5,521,207	05-28-1996	Graneto	All
	U8	US-5,273,760	12-28-1993	Oshlack et al.	All
	U9	US-5,286,493	02-15-1994	Oshlack et al.	All
	U10	US-5,324,351	06-28-1994	Oshlack et al.	All
	U11	US-5,356,467	10-18-1994	Oshlack et al.	All
	U12	US-5,366,738	11-22-1994	Rork et al.	All
	U13	US-5,472,712	12-05-1995	Oshlack et al.	All
	U14	US-5,510,496	04-23-1996	Talley et al.	All
	U15	US-5,563,165	10-08-1996	Talley et al.	All
	U16	US-5,631,250	05-20-1997	Bunnell et al.	All
	U17	US-5,633,272	05-27-1997	Talley et al.	All
	U18	US-5,703,232	12-30-1997	Bunnell et al.	All
	U19	US-5,736,541	04-07-1998	Bunnell et al.	All
	U20	US-5,753,688	05-19-1998	Talley et al.	All
	U21	US-5,760,068	06-02-1998	Talley et al.	All
	U22	US-5,932,598	08-03-1999	Talley et al.	All

Examiner	/Renee Claytor/	Date 00/40/0040	\neg
Signature	Thomas diayton	Considered U9/10/2010	لـ

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw line through distorn if not in conformance and not considered include copy of this form with next communication to applicant. "Applicant's unique citation designation number (optional)." See Kind Coties of USPTO Patent Drawn Concerned as wiveyus stopping, or MEPEP 0010-04. "Enter Office that issued not document, by the vice-letter code (VME) and and Table 1. "For Japanese patent documents, the indication of the year of the rings of the Emperor must proceed the serial number of the patent document." Kind of document by the approprise symbols as indicated on the document under WFO Standard 3.7. It of possible. "Applicant is to Stope a check mark here if English language." Translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1 14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 6 Attorney Docket Number

			U.S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No.	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U23	US-5,972,986	10-26-1999	Seibert et al.	All
	U24	US-5,985,902	11-16-1999	Talley et al.	All
	U25	US-6,054,136	04-25-2000	Farah et al.	All
	U26	US-6,132,420	10-17-2000	Dionne et al.	All
	U27	US-6,156,781	12-05-2000	Talley et al.	All
	U28	US-6,245,357	06-12-2001	Edgren et al.	All
	U29	US-6,270,787	08-07-2001	Ayer	All
	U30	US-6,283,953	09-04-2001	Ayer et al.	All
	U31	US-6,287,295	09-11-2001	Chen et al.	All
	U32	US-6,323,266	11-27-2001	Phillips	All
	U33	US-6,333,050	12-25-2001	Wong et al.	All
	U34	US-6,342,249	01-29-2002	Wong et al.	All
	U35	US-6,348,458	02-19-2002	Hamied et al.	All
	U36	US-6,365,185	04-02-2002	Ritschel et al.	All
	U37	US-6,368,626	04-09-2002	Bhatt et al.	All
	U38	US-6,375,978	04-23-2002	Kleiner et al.	All
	U39	US-6,384,034	05-07-2002	Simitchieva et al.	All
	U40	US-6,403,640	06-11-2002	Stoner et al.	All
	U41	US-6,413,965	07-02-2002	Mylari	All
	U42	US-6,420,394	07-16-2002	Supersaxo	All
	U43	US-6,579,895	06-17-2003	Karim et al.	All
	U44	US-6,613,790	09-02-2003	Carter	All

Examiner	(Donos Claytor)	Date	00/40/0040
Signature	/Henee Claytor/	Considered	09/10/2010
Carginatara		Considered	

"EXAMINER: Initial if reference considered, whether or not classion is in conformance with MPEP 800. Draw line through classion if not in conformance and not considered include copy of this form with next communication to applicate "Applicants" supplies obtained respiration number optionals. "See Kind Coles of USPTO Patent Documents at www.usdo.cog or MPEP901.04. "Enter Office that issued the document, be included recomment." Example of colument by a supplies the comment of the property of the properties of the

Institution is attached.

This collection of line is required by S7 CFR 197 and 198. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete.

105 PTO 10

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Complete if Known Substitute for form 1449A/PTO Application Number 10/660,202 INFORMATION DISCLOSURE Filing Date September 11, 2003 STATEMENT BY APPLICANT First Named Inventor Örn Almarsson (use as many sheets as necessary) Art Unit 1617 Examiner Name Deirdre R. Claytor of Attorney Docket Number Sheet 6 TPI.350C1

Examiner Initials*	Cite No. 1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U45	US-7,172,769	02-06-2007	Kararli et al.	All
	U46	US-7,205,413	04-17-2007	Morissette et al.	All
	U47	US-7,446,107	11-04-2008	Remenar et al.	All
	U48	US-7,452,555	11-18-2008	Childs	All
	U49	US-7,459,449	12-02-2008	Keltjens	All
	U50	US-2002/0013357	01-31-2002	Nadkarni et al.	All
	U51	US-2002/0006951	01-17-2002	Hageman et al.	All
	U52	US-2002/0015735	02-07-2002	Hedden et al.	All
	U53	US-2002/0034542	03-21-2002	Thombre et al.	All
	U54	US-2002/0071857	06-13-2002	Kararli et al.	All
	U55	US-2002/0107250	08-08-2002	Hariharan et al.	All
	U56	US-2002/0119193	08-29-2002	Le et al.	All
	U57	US-2004/0029946	02-12-2004	Arora et al.	All
	U58	US-2004/0154890	08-12-2004	Liu	All
	U59	US-2004/0242640	12-02-2004	Desai et al.	All
	U60	US-2005/0070551	03-31-2005	Remenar et al.	All
	U61	US-2007/0015841	01-18-2007	Tawa et al.	All
	U62	US-2007/0293674	12-20-2007	Scoppettuolo et al.	All
	U63	US-7,132,570	11-07-2006	Neckebrock et al.	All
	U64	US-			
	U65	US-			
	U66	US-			

Examiner	/Renee Claytor/	Date	09/10/2010
Signature	menee Glayion	Considered	03/10/2010

"EXAMINES: Initial Intercone considered, whether or not citation is in conformance with MPEP 609. Draw like through citation if not in conformance and not consistents include copy of this form with next communication to applicant." Applicant's unique citation designation number opinions See Mod Codas of USPTO Patent Decuments in sweetings. or MPEP901.04. "Siner Office that issued the document, by the two-letter code (WIPO Standard T3)." For Laganeses patent focuments, the indication of the year of the region of the Emperor must procedule he sental number of the patent occument for Mod of document to the patent occument. The indication of the year of the region of the Emperor must procedule he sental number of the patent occument. Will not of colument to the patent occument to the patent occument to the patent occument.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the soulic which is to file (and by the USFTO by process) an application. Confidentially is powered by 38 U.S. (1.22 and 37 CFR 1.14. This collection is estimated to late 2 bours to complete. Including pathening preparing, and submitting the completed application form to the USFTO. Time will vary depending upon the individual case. Any comments on the amount of fire you require to complete this form and/or suggestions for reducing this burder, should be sunt to the Chief Information Oriesr U.S. Pather and Trademark Office, P.O. Box 1450, Alexandria, VA. 2231-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 4450, Alexandria, VA. 2231-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

Complete if Known Substitute for form 1449B/PTO Application Number 10/660 202 INFORMATION DISCLOSURE Filing Date STATEMENT BY APPLICANT First Named Inventor (use as many sheets as necessary)

of

Sheet

September 11, 2003 Örn Almarsson Group Art Unit 1617 Examiner Name Deirdre R. Claytor 6 Attorney Docket Number TPI.350C1

		FOREIGN	PATENT DOCU	JMENTS	
Examiner Initials*	Cite No. 1	Foreign Patent Document Country Code 3 - Number 4 - Kind Code 5 (f known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns Lines Where Relevant Passages or Relevant Figures Appear
	F1	WO 01/45706	06-28-2001	Pharmacia Corporation	All
	F2	WO 2002/102376	12-27-2002	Pharmacia Corporation	All
	F3	WO 2002/10125	02-07-2002	Teva Pharmaceutical Industries Ltd.	All
	F4	WO 2002/056915	07-25-2002	Cephalon, Inc.	All
	F5	WO 2005/053612	06-16-2005	Shire Laboratories, Inc.	All
	F6	WO 96/33193	10-24-1996	Janssen Pharmaceutica N.V.	All
	F7	JP 54-095589	07-28-1979	Sumitomo Chemical Co. Ltd.	All
	F8	FR 2,849,029	06-25-2004	Laboratoire L. Lafon	All

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite Initials* No. 1		Include name of the author (in CAPITAL LETTERS), little of the article, (when appropriate), title of the item (book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	R1	BALL, P. "Scandal of crystal design" <i>Nature</i> , June 20, 1996, pp. 648-650, Vol. 381.	
	R2	BASTIN, R. J. et al. "Salt Selection and Optimization Procedures for Pharmaceutical New Chemical Entities" Organic Process Research & Development, 2000, pp. 427-435, Vol. 4, No. 5.	
	R3	BERNSTEIN, J. et al. "Concomitant Polymorphs" Angew. Chem. Int. Ed., 1999, pp. 3440-3461, Vol. 38.	
	R4	BOUCHER, E. et al. "Use of Hydrogen Bonds to Control Molecular Aggregation. Behavior of Dipyridones and Pyridone-Pyrimidones Designed to Form Cyclic Triplexes" J. Org. Chem., 1995, pp. 1408-1412, Vol. 60.	

Examiner Signature	/Renee Claytor/ Date Considered 09/10/2010
ESCHARGE LAND	A MOCD COS Development of the Cost of the

and not considered include copy of this form with next communication to applicant.

Applicant is unique catation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 3° CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gardening, pepaling, and scommon of the complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1456. Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Co	omplete if Known	_
Application Number	10/660,202	
Filing Date	September 11, 2003	
First Named Inventor	Örn Almarsson	
Group Art Unit	1627	
Examiner Name	Deirdre R. Claytor	

Sheet 5 of 6 Attorney Docket Number TPI 350C1

		NON PATENT LITERATURE DOCUMENTS	7
Examiner Initials*	Cite No. 1	include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the ltem (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R5	BRITTAIN, H. G., <u>Polymorphism in Pharmaceutical Solids</u> , Marcel Dekker, Inc., 1999, pp. 183, 202-208 and 219.	
	R6	CHANG, Y. et al. "An Approach to the Design of Molecular Solids. Strategies for Controlling the Assembly of Molecules into Two-Dimensional Layered Structures" J. Am. Chem. Soc., 1993, pp. 5991-6000, Vol. 115.	
	R7	COWAN, J. A. et al. "Neutron diffraction studies of the 1:1 and 2:1 cocrystals of benzene- 1,2,4,5-tetracarboxylic acid and 4,4-bipyridine" Acta Cryst., 2006, pp. o157-o161, Vol. C62.	
	R8	DAVIDOVICH, M. et al. "Detection of Polymorphism by Powder X-Ray Diffraction: Interference by Preferred Orientation" <i>American Pharmaceutical Review</i> , 2004, pp. 10, 12, 14, 16, and 100, Vol. 7, Issue 1.	
	R9	DAVIES, N. M. et al. "Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib. A Selective Cyclo-Oxygenase-2 Inhibitor" Clin. Pharmacokinet., March 2000, pp. 225-242, Vol. 38, No. 3.	
	R10	DEAN, J A., Analytical Chemistry Handbook, McGraw-Hill, Inc., 1995, pp. 10.24-10.26.	
	R11	Definition of solvate, The Free Dictionary, http://www.thefreedictionary.com/solvate , accessed online on 21 July 2009, pp. 1-3.	
	R12	DESIRAJU, G.R. "Solid-State Chemistry: Crystal Gazing: Structure Prediction and Polymorphism" Science, October 17, 1997, pp. 404-405, Vol. 278, No. 5337.	
	R13	DOELKER, E. "Physicochemical behavior of active substances. Consequences for the feasibility and stability of pharmaceutical forms" <i>STP Pharma Pratiques</i> , 1999, pp. 399-409, Vol. 9, No. 5.	
	R14	DOELKER, E. "Cystalline modifications and polymorphism changes during drug manufacturing" <i>Annales Pharmaceutiques Francaises</i> , 2002, pp. 161-176, Vol. 60, No. 3.	
	R15	DUNITZ, J. D. "Are crystal structures predictable?" Chem Commun., 2003, pp. 545-548.	
	R16	FEYNMAN, R. P. "There's Plenty of Room at the Bottom" Engineering and Science, February 1960, pp. 22-36.	
	R17	JAIN, N. K. et al. "Polymorphism in Pharmacy" Indian Drugs, 1986, pp. 315-329, Vol. 23. No. 6.	

Examiner /Renee Claytor/	Date 09/10/2010	
--------------------------	-----------------	--

*EXAMINER: Intal if reference considered, whether or not dation is in conformance with MFEP 609. Draw line through citation if not in conformance and not considered inclusive copy of his form with next communication to applicate inclusive copy of his form with next communication to applicate the properties of the pro

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain is benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 38 U.S. C. 122 and 37 CFR 1.14. This collection is estimated to fairs 2 between the complete, inclining pathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete ints from another suggestions for reducing this busides, should be sent to the OFER from the USPTO. The will reduce the Section of the USPTO time will reduce the Complete ints from another suggestions for reducing this busides, should be sent to the OFER from the Complete Trademark Office, P.O. Box 1450, Alexandria, VA. 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 4450, Alexandria, VA. 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

Substitute for form 1449B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Sheet

6 Attorney Docket Number TPI 350C1

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. 1	include name of the author (in CAPITAL LETTERS), site of the article, (when appropriate), title of the item (book, magazen, journal, serial, symposium, catalog, etc.), data, page(s, volumer-issue number(s), publisher, city and/or country where published. KIRCHNER, M. T. <i>et al.</i> , Co-crystals with Acetylene: Small is not Simple!" <i>Chem. Eur. J.</i> 2010, pp. 2131-2146, Vol. 16.				
	R18					
	MOULTON, B. et al. "From Molecules to Crystal Engineering: Supramolecular Isomerist and Polymorphism in Network Solids" Chem. Rev., 2001, pp. 1629-1658, Vol. 101.					
	R20	MUZAFFAR, N. A. et al. "Polymorphism and Drug Availability" Journal of Pharmacy, 1979, pp. 59-66, Vol. 1, No. 1.				
	R21	OSORIO-LOZADA, A. et al. "Synthesis and determination of the absolute stereochemistry of the enantiomers of adrafinil and modafinil" <i>Tetrahedron: Asymmetry</i> , 2004, pp. 3811-3815, Vol. 15.				
	R22	OTSUKA, M. et al. "Effect of Polymorphic Forms of Bulk Powders on Pharmaceutical Properties of Carbamazepine Granules" Chem. Pharm. Bull., 1999, pp. 852-856, Vol. 47, No. 6.				
	R23	SHATTOCK, T. R. et al. "Hierarchy of Supramolecular Synthons: Persistent Carboxylic Acid- Pyridine Hydrogen Bonds in Cocrystals That also Contain a Hydroxyl Moiety" Cryst. Growth Des., 2008, pp. 4533-4545, Vol. 8, No. 12.				
	R24	THAYER, A. M. "Form and Function: The choice of pharmaceutical crystalline form can be used to optimize drug properties, and cocrystals are emergiing as new alternatives" Chemical & Engineering News, June 18, 2007, pp. 17-30, Vol. 85, No. 25.				
	R25	U.S. Pharmacopia #23, 1995, p. 1843.				
	R26	VILLA, L. A. et al. "Central Nervous System Paracoccidioidomycosis. Report of a Case Successfully Treated with Itraconazol" Rev. Inst. Med. Trop. S. Paulo, July-August 2000, pp. 231-234, Vol. 42, No. 4.				
	R27	ZAWOROTKO, M. J. "Crystal Engineering of Diamondoid Networks" Chemical Society Reviews, 1994, pp. 283-288, Vol. 23.				
	R28	KLEIN, C. L. et al. "Molecular Structure of Two Conformationally Restrained Fentanyl Analogues: cis- and trans-Isomers of N-[3-Methyl-1-12-(1,2,3,4-tetrahydro)naphthyl]-4-piperidinyl]-N-phenylpropanamide" Journal of Pharmaceutical Sciences, November 1985, pp. 1147-1151, Vol. 74, No. 11.				
	R29					

Examiner Signature	/Renee Claytor/	Date Conside	ered	09/10/2010
"EXAMINER. Initial if	reference considered, whether or not citation is in conformance with MPE	P 609. Draw	line throu	ugh citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

Applicant unique describ designation number (plotolisis). Applicant is so pace a critical traits need in application plant intermediate in course by 97 CPR 1.89. The information is required by 45 CPR 1.89. The information is required to destroy release a critical traits. The public which is 66 gired by the USPTO Time solicities on the public which is 66 gired by the USPTO Time solicities on the public which is 66 gired by the USPTO Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form another suggestions for including this budges, should be sent to the Other Information and Traidemark Office, P.O. Box 1450. Alexandria, VA. 2231-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1450. Alexandria, VA. 2231-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1450. Alexandria, VA. 2231-1450.